MYO7A_HUMAN,S1106T,0.142,-,-,-
MYO7A_HUMAN,R1108K,0.257,-,-,-
MYO7A_HUMAN,V1126D,0.753,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K1128 (Pr = 0.22 | P = 0.03); Altered Disordered interface (Pr = 0.18 | P = 0.05), ELME000052|ELME000053|ELME000063|ELME000220|PS00006,-
MYO7A_HUMAN,T1127S,0.213,-,-,-
MYO7A_HUMAN,Q1138R,0.238,-,-,-
MYO7A_HUMAN,I1157V,0.181,-,-,-
MYO7A_HUMAN,A1166T,0.336,-,-,-
MYO7A_HUMAN,K1281R,0.099,-,-,-
MYO7A_HUMAN,I1323V,0.223,-,-,-
MYO7A_HUMAN,S1358F,0.383,-,-,-
MYO7A_HUMAN,E1359D,0.249,-,-,-
MYO7A_HUMAN,N1365H,0.584,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Loss of Allosteric site at Y1368 (Pr = 0.21 | P = 0.04), ELME000052,-
MYO7A_HUMAN,S1402C,0.592,Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Sulfation at Y1400 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,Y1416S,0.815,Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Gain of O-linked glycosylation at T1415 (Pr = 0.11 | P = 0.05), ELME000182|PS00006,-
MYO7A_HUMAN,T1427N,0.250,-,-,-
MYO7A_HUMAN,A1445T,0.249,-,-,-
MYO7A_HUMAN,A1451S,0.087,-,-,-
MYO7A_HUMAN,G1481V,0.859,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Strand (Pr = 0.28 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Loss of Sulfation at Y1477 (Pr = 0.01 | P = 0.04), ELME000063|ELME000085|ELME000155,-
MYO7A_HUMAN,A1540G,0.150,-,-,-
MYO7A_HUMAN,P1541S,0.183,-,-,-
MYO7A_HUMAN,H1542Q,0.157,-,-,-
MYO7A_HUMAN,H1542R,0.173,-,-,-
MYO7A_HUMAN,S1543L,0.139,-,-,-
MYO7A_HUMAN,L1548V,0.253,-,-,-
MYO7A_HUMAN,T1549I,0.205,-,-,-
MYO7A_HUMAN,P1553S,0.370,-,-,-
MYO7A_HUMAN,P1556L,0.425,-,-,-
MYO7A_HUMAN,C1557Y,0.591,Altered Ordered interface (Pr = 0.31 | P = 2.4e-03); Gain of Strand (Pr = 0.28 | P = 8.7e-03); Loss of Loop (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Disulfide linkage at C1560 (Pr = 0.10 | P = 0.05), ELME000053|ELME000136|ELME000162|ELME000337,-
MYO7A_HUMAN,T1566V,0.125,-,-,-
MYO7A_HUMAN,A1567V,0.206,-,-,-
MYO7A_HUMAN,I1575L,0.374,-,-,-
MYO7A_HUMAN,I1575M,0.450,-,-,-
MYO7A_HUMAN,A1618V,0.113,-,-,-
MYO7A_HUMAN,N1645T,0.616,Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Altered DNA binding (Pr = 0.14 | P = 0.05), ELME000085,-
MYO7A_HUMAN,T1656N,0.760,Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Altered DNA binding (Pr = 0.18 | P = 0.03), None,-
MYO7A_HUMAN,Q1658H,0.478,-,-,-
MYO7A_HUMAN,T1664M,0.324,-,-,-
MYO7A_HUMAN,M1686L,0.254,-,-,-
MYO7A_HUMAN,D1689A,0.383,-,-,-
MYO7A_HUMAN,V1695A,0.156,-,-,-
MYO7A_HUMAN,R1701H,0.131,-,-,-
MYO7A_HUMAN,A1703P,0.228,-,-,-
MYO7A_HUMAN,A1703T,0.081,-,-,-
MYO7A_HUMAN,Y1719L,0.762,Loss of Phosphorylation at Y1719 (Pr = 0.47 | P = 5.0e-03); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.1e-03), ELME000120|ELME000147,-
MYO7A_HUMAN,Y1721R,0.732,Loss of Phosphorylation at Y1721 (Pr = 0.46 | P = 5.2e-03); Gain of Intrinsic disorder (Pr = 0.43 | P = 4.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 8.7e-03), ELME000120|ELME000182,-
MYO7A_HUMAN,P1725Q,0.779,Gain of Phosphorylation at Y1721 (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.3e-03), None,-
MYO7A_HUMAN,K1727A,0.820,Altered Disordered interface (Pr = 0.17 | P = 0.05), None,-
MYO7A_HUMAN,M1734E,0.659,Altered Disordered interface (Pr = 0.48 | P = 3.3e-03); Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01), ELME000064|PS00006,-
MYO7A_HUMAN,A1738V,0.145,-,-,-
MYO7A_HUMAN,R1739D,0.833,Altered Disordered interface (Pr = 0.61 | P = 6.0e-04); Gain of B-factor (Pr = 0.24 | P = 0.04), ELME000321|PS00006,-
MYO7A_HUMAN,K1741R,0.302,-,-,-
MYO7A_HUMAN,T1748F,0.737,Altered Disordered interface (Pr = 0.26 | P = 0.01); Gain of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000173,-
MYO7A_HUMAN,R1749V,0.707,Altered Disordered interface (Pr = 0.31 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04); Gain of Proteolytic cleavage at W1745 (Pr = 0.13 | P = 0.02), None,-
MYO7A_HUMAN,K1753E,0.543,Altered Disordered interface (Pr = 0.18 | P = 0.05), ELME000146,-
MYO7A_HUMAN,K1753P,0.694,Altered Disordered interface (Pr = 0.18 | P = 0.05), ELME000146,-
MYO7A_HUMAN,A1755G,0.278,-,-,-
MYO7A_HUMAN,L1760Q,0.440,-,-,-
MYO7A_HUMAN,L1761A,0.350,-,-,-
MYO7A_HUMAN,G1762L,0.480,-,-,-
MYO7A_HUMAN,S1763N,0.133,-,-,-
MYO7A_HUMAN,S1767R,0.373,-,-,-
MYO7A_HUMAN,C1771S,0.880,, ELME000147|ELME000197,-
MYO7A_HUMAN,I1775T,0.373,-,-,-
MYO7A_HUMAN,K1779H,0.862,Altered Ordered interface (Pr = 0.27 | P = 0.05); Loss of Acetylation at K1779 (Pr = 0.25 | P = 0.01); Loss of Allosteric site at Y1780 (Pr = 0.23 | P = 0.02); Gain of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.04), ELME000041,-
MYO7A_HUMAN,Y1780T,0.932,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Allosteric site at Y1780 (Pr = 0.28 | P = 7.1e-03); Loss of Acetylation at K1779 (Pr = 0.22 | P = 0.03); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), ELME000041|ELME000220|PS00006,-
MYO7A_HUMAN,T1789V,0.325,-,-,-
MYO7A_HUMAN,P1808A,0.481,-,-,-
MYO7A_HUMAN,Q1816H,0.856,Altered Disordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000081|ELME000083|ELME000120|ELME000182,-
MYO7A_HUMAN,F1844Y,0.462,-,-,-
MYO7A_HUMAN,I1849V,0.071,-,-,-
MYO7A_HUMAN,L1851V,0.602,, None,-
MYO7A_HUMAN,Q1855S,0.728,, ELME000239,-
MYO7A_HUMAN,S1860P,0.699,, ELME000102|ELME000106|ELME000336|PS00005,-
MYO7A_HUMAN,R1861W,0.534,, ELME000102|ELME000233|ELME000328|ELME000336|PS00005,-
MYO7A_HUMAN,V1918A,0.854,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Loss of Strand (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Stability (Pr = 0.11 | P = 0.04), ELME000239,-
MYO7A_HUMAN,V1918E,0.952,Gain of Intrinsic disorder (Pr = 0.45 | P = 3.8e-03); Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of B-factor (Pr = 0.29 | P = 4.0e-03); Loss of Strand (Pr = 0.26 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000117,-
MYO7A_HUMAN,K1923P,0.713,Altered Ordered interface (Pr = 0.36 | P = 3.2e-03); Loss of Helix (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000136|ELME000153|ELME000159|PS00005,-
MYO7A_HUMAN,N1930G,0.366,-,-,-
MYO7A_HUMAN,N1930S,0.139,-,-,-
MYO7A_HUMAN,I1931H,0.850,Altered Metal binding (Pr = 0.23 | P = 0.04), ELME000052|ELME000313,-
MYO7A_HUMAN,T1933S,0.100,-,-,-
MYO7A_HUMAN,R1934G,0.724,, ELME000052|ELME000106|ELME000146|ELME000313,-
MYO7A_HUMAN,R1934S,0.664,, ELME000052|ELME000106|ELME000146|ELME000313|ELME000335,-
MYO7A_HUMAN,L1936V,0.304,-,-,-
MYO7A_HUMAN,F1946L,0.924,Altered Stability (Pr = 0.10 | P = 0.04), ELME000041|ELME000149|ELME000335,-
MYO7A_HUMAN,F1946S,0.944,Altered Stability (Pr = 0.40 | P = 2.9e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000336|PS00005,-
MYO7A_HUMAN,I1949V,0.480,-,-,-
MYO7A_HUMAN,A1950I,0.445,-,-,-
MYO7A_HUMAN,A1950L,0.594,Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000333,-
MYO7A_HUMAN,V1984L,0.335,-,-,-
MYO7A_HUMAN,V1984M,0.401,-,-,-
MYO7A_HUMAN,T2000S,0.219,-,-,-
MYO7A_HUMAN,R2061Q,0.236,-,-,-
MYO7A_HUMAN,V2072I,0.041,-,-,-
MYO7A_HUMAN,N2124H,0.348,-,-,-
MYO7A_HUMAN,K2135H,0.859,Altered Transmembrane protein (Pr = 0.21 | P = 4.3e-03); Altered Metal binding (Pr = 0.19 | P = 0.02), None,-
MYO7A_HUMAN,K2156S,0.861,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000239,-
MYO7A_HUMAN,N2159L,0.864,Altered Ordered interface (Pr = 0.44 | P = 4.0e-04); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Gain of Loop (Pr = 0.29 | P = 8.4e-03); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000336|PS00001,-
MYO7A_HUMAN,Y2166V,0.881,Altered Ordered interface (Pr = 0.35 | P = 4.8e-03); Loss of Loop (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000120|ELME000182,-
